Biologicals and tsDMARDs in inflammatory rheumatic diseases: The Reade Rheumatology Registry
Recruiting
- Conditions
- inflammatory rheumatic diseases, biologic agents, targeted synthetic DMARD, safety, efficacy, dose reduction strategy
- Registration Number
- NL-OMON28595
- Lead Sponsor
- Reade Rheumatology, Amsterdam
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis/non-radiographic axial spondyloarthritis, according to the treating rheumatologist;
- Written informed consent.
Exclusion Criteria
None
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy will be determined in comparison to baseline by comparing disease activity, patient reported outcomes, radiological progression and functional capacity during follow-up.<br /><br>Safety will be determined by the occurrence of side effects.
- Secondary Outcome Measures
Name Time Method Changes in (bio)markers during treatment will be analyzed versus baseline.<br>